EUVIMEDOpdag EUVIMED
Crossref

Immunohistochemical expression of mTOR protein in breast carcinoma tissues

The Internet Journal of Laboratory Medicine · 2010

DOI: 10.5580/1c52 ↗

At a glance

Journal article in The Internet Journal of Laboratory Medicine, 2010.

AbstractBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

The mTOR kinase plays a central role in coordinating cell growth in response to mitogens, amino acid and energy sufficiency. The pathway leading to mTOR activation by these factors, usually results in increased protein biosynthesis and cell cycle progression. mTOR is also a key regulatory component that controls the induction of autophagy. Aberrant expression of the mTOR signaling pathway molecules and autophagy has been linked to tumorigenesis.

Objective

To determine the mTOR protein expression in breast cancer and normal breast tissues and to determine the relationships between clinicopathological parameters of the breast tumors and mTOR expression. Methods: mTOR protein expression was determined using immunohistochemistry approach in 78 cases of breast cancer tissues and 53 cases of normal breast tissues.

Results

A significantly higher number of breast cancer tissues were found to express the mTOR protein in various grades of intensity as compared to the normal breast tissues. However, there were no significant relationship between clinicopathological variables (age group, clinical stage and receptor status) and mTOR protein expression.

Conclusion

A significantly higher number of breast cancer tissues were found to express the mTOR protein with strong immunoreactivity as compared to the normal tissues, further supported the current findings that over-expression of mTOR protein may contribute to the development of breast cancers This work is carried out at the Advanced Medical and Dental Institute, Universiti Sains Malaysia and supported by Sciencefund, MOSTI, Malaysia. The mammalian target of rapamycin, commonly known as mTOR, is a serine/threonine kinase which belongs to the family of phosphatidylinositol kinase-related kinase (PIKK). TOR was discovered in Saccharomyces cerevisiae as product of a gene whose mutation confers resistance to growth inhibition by the macrolide antibiotic, rapamycin (Kunz et al 1993). mTOR plays a critical role in coordinating cell growth in response to mitogens, amino acid and energy sufficiency (Schmelzle & Hall 2000). The pathway leading to mTOR activation by these factors, usually results in an increased protein biosynthesis, cell growth and G1 cell cycle progression (Seeliger et al 2007). The cell growth promoting effects of mTOR are mediated by two proteins which regulate protein translation, namely p70S6K and 4E-BP1 (Proud 2004). mTOR phosphorylates p70S6K which leads to the phosphorylation of ribosomal protein S6 and subsequently to the translation of mRNA which encodes for ribosomal proteins and elongation factors (Jacinto & Hall 2003; Proud 2004). 4E-BP1, a binding protein and translational repressor, upon phosphorylation by mTOR, will release the initiation factor eIF4E. Phosphorylation of 4E-BP1 disrupts its interaction with the eIF4E translation initiation factor, allowing eIF4E to bind to the cap structure at the 5’end of mRNAs, which subsequently promotes ribosome recruitment and initiation of translation (Gera et al 2004). In a recent study, p-4E-BP1 was found to be the main factor in signaling pathways which was associated with prognosis and grade of malignancy in breast tumors. Expression of p-4E-BP1 was correlated with a high tumor proliferation rate (Rojo et al 2007). mTOR activation by mitogens is mediated by upstream phosphatidylinositol 3-kinase-AKT pathway (Chiang & Abraham 2005). The first event in the activation process of mTOR is the binding of growth factors (eg. insulin) to their receptors. In response to that, class I PI3Ks promote the conversion of the membrane lipid phosphatidylinositol 4, 5 biphosphate (PIP2) into phosphatidyl-inositol 3,4,5triphosphate (PIP3) (Seeliger et al 2007). Activation of AKT by PIP3 is a central event in the signaling cascade. However Immunohistochemical expression of mTOR protein in breast carcinoma tissues 2 of 11 PIP3 can be reconverted to PIP2 by the lipid phosphatase activity of the tumor suppressor PTEN (Neufeld 2003). PTEN is frequently mutated in many cancers and in a group of cancer-like syndromes that are characterized by the emergence of hamartomas (Inoki et al 2005). A critical outcome of PTEN inactivation is an increase in mTOR activity, resulting in the phosphorylation of 4E-BP1 and S6K, and subsequently uncontrolled cell growth. The Akt pathway is found to be activated early in breast cancer cases (Bose et al 2006). Interestingly, mTOR kinase is also a key regulatory component that controls the induction of autophagy. Inhibition of mTOR (by nutrient-depletion, starvation and rapamycin) leads to cell cycle arrest, inhibition of cell proliferation, immunosuppression and induction of autophagy. Increased levels of the mTOR kinase is found to inhibit the autophagy process resulting in an increased in cell growth and tumor development. The first potent inhibitor of mTOR, rapamycin, is known to promote autophagy and inhibits the growth of malignant glioma cells (Takeuchi et al 2005). Autophagy, an intra-lysosomal degradation pathway that controls cell growth by allowing the turnover of damaged long-lived proteins and organelles, is an important process for normal development and are implicated in various pathophysiological conditions, including breast cancers (Cuervo 2004; Levine 2007; Levine & Kroemer 2008; Liang et al 1999). Deregulation of the mTOR signaling pathway and aberrant autophagy is associated with oncogenesis (Bialik & Kimchi 2008; Chiang & Abraham 2007; Cully et al 2006). Targeting the mTOR pathway using mTOR inhibitors in cancer have become widely appreciated only recently. It is suggested that by pharmacologically inhibiting mTOR, cells will be conditioned to halt cell cycle progression and results in G1 arrest and subsequently autophagy (Gera et al 2004). Patients with tumors expressing high level of mTOR kinase expression are expected to benefit from treatment from the mTOR kinase inhibitors. Rapamycin is an example of a prototype of mTOR inhibitor and many mTOR inhibitors are currently in development. The mTOR inhibitor, CCI-779 (temsirolimus) is a recently Food and Drug Administration (FDA), USA–approved anticancer drug with efficacy in certain solid tumors and hematologic malignancies (Shor et al 2008). In addition, another mTOR inhibitor, RAD001 (everolimus) is currently in Phase II/III clinical trials for various cancers, including breast cancers (Campone et al 2009; Seeliger et al 2007). The aims of this study were to determine the mTOR protein expression in breast cancer and normal breast tissues by standard immunohistochemistry method. In addition, this study attempts to determine the relationship between the expression of this protein with type of tissues and clinicopathological characteristics of the breast tumors. Finally, by determining the proportion of breast cancer which expresses mTOR protein, it may provide us some clue on the proportion of breast cancer patients whom may be benefit from mTOR inhibitors. MATERIALS AND METHODS TISSUE MICROARRAYS AND ANTIBODIES Paraffin embedded tissue microarray slides consisting of breast cancer tissues (BR701) and normal breast tissues (BRN801) were purchased from Biomax (USA). The normal breast tissue microarray (BRN801) consists of tumor adjacent normal breast tissues cores and breast cancer tissue cores. The breast cancer tissue microarrays were provided with data on patient’s age, tumor receptor status (ER, PR and c-erb-2) and clinical stage. The rabbit monoclonal antimTOR (human) antibody was obtained from Abcam (UK). Rabbit IgG (Sigma Aldrich, USA) was used instead of primary antibody in negative controls. Human breast cancer slides known to be positive for mTOR protein were used as positive controls for all experiments. IMMUNOHISTOCHEMISTRY DETECTION OF MTOR PROTEIN IN TISSUES The breast cancer tissue and normal breast tissue microarray slides were immunohistochemically examined with antimTOR antibody (Abcam, UK). Briefly, deparaffinization of the tissue microarray slides and control tissue sections was carried out by heat treatment at 60Cfor 30 min. This was followed by rehydration through a series of graded alcohol to water. Endogenous peroxidase activity was blocked by incubating the sections in two changes of 3% (v/v) H2O2 in phosphate buffered saline (PBS) (pH 7.4) at room temperature. Tris-EDTA acid buffer, pH 9.0 at 1mM was used for antigen retrieval according to standard procedures. Immunohistochemistry procedures and antibody titration was carried out using Dako REALTM EnVisionTM Detection System, (Dako, USA). Briefly, the slides were rinsed with PBS for 5 min, and non-specific antibody binding was blocked by incubation of the tissue array slides with horse serum before proceeding to the primary antibodies. Immunostaining was visualized using DAB chromogen (Dako, USA). Positive staining to mTOR was recognized under light microscope as a diffuse cytoplasmic brown color Immunohistochemical expression of mTOR protein in breast carcinoma tissues 3 of 11 stain. The optimized dilution for mTOR antibody was determined at 1:50. ASSESSMENTS OF MTOR IMMUNOSTAINING AND STATISTICAL ANALYSIS Assessments were carried out by an independent pathologist and a researcher. A consensus opinion was arrived on the intensity of staining. For each array, whole cores were assessed either as negative or positive for mTOR stain. The positive cores were then graded as weak (1+), moderate (2+) or strong (3+) according to the intensity of staining. Data was recorded and statistically analyzed using Chi-Square test to determine the relationship between mTOR protein expression in breast cancer tissues in comparison to normal breast tissues. The association between mTOR protein expression in breast cancer tissues and clinicopathological variables were also examined. Statistical analysis of the data was performed using SPSS Software (Version 12). All experiments were carried out in duplicate.

Cite

APA

(2010). Immunohistochemical expression of mTOR protein in breast carcinoma tissues. The Internet Journal of Laboratory Medicine. https://doi.org/10.5580/1c52

Vancouver

Immunohistochemical expression of mTOR protein in breast carcinoma tissues. The Internet Journal of Laboratory Medicine. 2010. doi:10.5580/1c52

BibTeX
@article{euvimed2010,
  title = {Immunohistochemical expression of mTOR protein in breast carcinoma tissues},
  journal = {The Internet Journal of Laboratory Medicine},
  year = {2010},
  doi = {10.5580/1c52}
}
Start for free →